January 21, 2009 — Glioblastoma multiforme has 4 distinct molecular subtypes, according to new data emerging from The Cancer Genome Atlas (TCGA) Research Network. The different subtypes show varying ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to WP1122 for the treatment of glioblastoma multiforme, according to a ...

Ottawa, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The global glioblastoma multiforme treatment market size is predicted to increase from USD 3.01 billion in 2025 to approximately USD 5.68 billion by 2033, ...

Glioblastoma multiforme (GBM) is the most common and aggressive type of tumor arising from star shaped cells called as astrocytes that make up supportive tissue of the brain. GBM has long baffled ...

SYDNEY, May 01, 2026 (GLOBE NEWSWIRE) -- EnGeneIC Limited today announced that the first patient has been dosed in its clinical trial evaluating EnGeneIC’s investigational EGFR-targeted EDV™ (EnGeneIC ...

Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "Glioblastoma Multiforme Treatment Market Forecast to 2033" has been added to ResearchAndMarkets.com's offering. The global Glioblastoma Multiforme (GBM) ...

CNS Pharmaceuticals Inc. CNSP shares are up during Monday’s premarket session following the announcement of an oversubscribed ...

Gleolan, a dye used for brain imaging, can help surgeons visualize tumor tissue during surgery for glioblastoma multiforme. Malignant transformation occurs from aggregation of genetic alterations and ...

DUBLIN--(BUSINESS WIRE)--The "Glioblastoma Multiforme (GBM) - Market Insights, Epidemiology and Market Forecast- 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. The report ...

Glioblastoma multiforme is the most common malignant primary brain tumor in adults. Mean progression-free survival is just over 6 months; treatment with surgical resection, chemotherapy, and radiation ...